ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

PDSB PDS Biotechnology Corporation

3.89
0.16 (4.29%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
PDS Biotechnology Corporation PDSB NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.16 4.29% 3.89 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.85 3.74 3.96 3.82 3.73
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
23/1/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202415:31EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/1/202416:10EDGAR2Form 8-K - Current report
22/1/202415:45GLOBEPDS Biotech Announces Retirement of Lauren V. Wood, M.D.,..
16/1/202407:00GLOBEPDS Biotech to Participate at B. Riley Securities 4th Annual..
04/12/202315:50GLOBEPDS Biotechnology Reports Inducement Grant Under Nasdaq..
04/12/202315:02EDGAR2Form 8-K - Current report
28/11/202306:30GLOBEPDS Biotech Appoints Lars Boesgaard as Chief Financial..
28/11/202305:02EDGAR2Form 8-K - Current report
14/11/202306:30GLOBEPDS Biotech Reports Third Quarter 2023 Financial Results and..
09/11/202315:07EDGAR2Form 8-K - Current report
09/11/202307:00GLOBEPDS Biotech Announces Updated Survival Data from NCI-Led..
07/11/202307:00GLOBEPDS Biotechnology Announces Conference Call and Webcast for..
23/10/202315:06EDGAR2Form 8-K - Current report
23/10/202307:00GLOBEPDS Biotech Announces Preliminary Biomarker Study Results in..
11/10/202315:02EDGAR2Form 8-K - Current report
11/10/202307:00GLOBEPDS Biotech Announces Interim Safety and Immune Response..
03/10/202315:03EDGAR2Form 8-K - Current report
03/10/202315:03EDGAR2Form 8-K - Current report
03/10/202308:02EDGAR2Form 8-K - Current report
03/10/202306:00GLOBEPDS Biotech Announces Interim 24-Month Survival Rate of 74%..
02/10/202315:05EDGAR2Form 8-K - Current report
02/10/202307:00GLOBEPDS Biotech Announces PDS0101 Combined with..
26/9/202307:00GLOBEPDS Biotech to Present at the LD Micro Main Event XVI
25/9/202307:00GLOBEPDS Biotech Reschedules Key Opinion Leader Roundtable..
20/9/202315:10EDGAR2Form 8-K - Current report
20/9/202315:05GLOBEPDS Biotech to Participate in the 2023 Cantor Fitzgerald..
20/9/202307:00GLOBEPDS Biotech Announces PDS0202 Elicits Active Neutralization..
13/9/202307:00GLOBEPDS Biotech to Host Key Opinion Leader Roundtable Addressing..
11/9/202315:05EDGAR2Form 8-K - Current report
08/9/202305:02EDGAR2Form 8-K - Current report
06/9/202315:05GLOBEPDS Biotech to Participate at the H.C. Wainwright 25th..
06/9/202307:00GLOBEPDS0202 Universal Influenza Preclinical Ferret Data to be..
18/8/202315:04EDGAR2Form 8-K - Current report
17/8/202315:05EDGAR2Form 8-K - Current report
16/8/202307:00GLOBEPDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial..
14/8/202315:05EDGAR2Form 8-K - Current report
14/8/202312:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202306:30GLOBEPDS Biotech Reports Second Quarter 2023 Financial Results..
14/8/202306:00GLOBEPDS Biotech Announces Submission of Phase 3 Protocol to FDA..
07/8/202307:00GLOBEPDS Biotechnology Announces Conference Call and Webcast for..
02/8/202307:00GLOBEPDS Biotech to Present at BTIG Virtual Biotechnology..
25/7/202315:01EDGAR2Form 8-K - Current report
25/7/202307:00GLOBEPDS Biotech to Present Immune Response Data from Combination..
17/7/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202316:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202316:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/7/202316:24EDGAR2Form 8-K - Current report
17/7/202316:23EDGAR2Form 8-K - Current report
17/7/202307:00GLOBEPDS Biotech Announces Acceptance of Abstract on Combination..

Su Consulta Reciente

Delayed Upgrade Clock